序号 |
标题 |
次数 |
作者 |
发布时间 |
72586 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
59 |
WYQ |
2024-12-19 |
72587 |
CAS: 2768446-73-5,DBCO-Val-Cit-PAB-MMAE |
72 |
WYQ |
2024-12-19 |
72588 |
MC-vc-PAB-C6-a-amanitin, ADC试剂 |
62 |
kx |
2024-12-19 |
72589 |
cas:663598-98-9,2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate,ADC定制 |
78 |
wyh |
2024-12-19 |
72590 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
82 |
zyl |
2024-12-19 |
72591 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate,ADC定制 |
88 |
wyh |
2024-12-19 |
72592 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
109 |
zyl |
2024-12-19 |
72593 |
Gly3-vc-PAB-MMAE, ADC试剂 |
90 |
kx |
2024-12-19 |
72594 |
CAS: 1869126-64-6, Azido-PEG4-Val-Cit-PAB-MMAE |
72 |
WYQ |
2024-12-19 |
72595 |
cas:2353409-54-6 , Mal-amido-PEG8-Val-Gly,ADC定制 |
88 |
wyh |
2024-12-19 |
72596 |
Azido-PEG4-Val-Ala-PAB-PNP |
87 |
zyl |
2024-12-19 |
72597 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
74 |
h |
2024-12-19 |
72598 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid,ADC定制 |
82 |
wyh |
2024-12-19 |
72599 |
CAS: 1343476-44-7,Val-Ala-PAB-OH |
70 |
WYQ |
2024-12-19 |
72600 |
MC-PBD, ADC试剂 |
83 |
kx |
2024-12-19 |
72601 |
Mal-Val-Ala-PAB的介绍 |
81 |
zyl |
2024-12-19 |
72602 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
70 |
h |
2024-12-19 |
72603 |
Azide-PEG3-Val-Cit-PAB-MMAF,叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
70 |
WYQ |
2024-12-19 |
72604 |
Arm-DOTA-B72.3 |
71 |
h |
2024-12-19 |
72605 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
86 |
zyl |
2024-12-19 |
72606 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
120 |
h |
2024-12-19 |
72607 |
1801838-28-7,Mc-vc-PAB-SN38,化合物MC-VC-PAB-SN38 |
78 |
kx |
2024-12-19 |
72608 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
76 |
h |
2024-12-19 |
72609 |
CAS: 863971-17-9,MC-Val-Cit-PAB-MMAF |
98 |
WYQ |
2024-12-19 |
72610 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
115 |
zyl |
2024-12-19 |
72611 |
DBCO-PEG4-vc-PAB-MMAE, ADC试剂 |
101 |
kx |
2024-12-19 |
72612 |
1884578-00-0,Boc-PEG4-Val-Ala-PAB-PNP,ADC定制 |
102 |
wyh |
2024-12-19 |
72613 |
DOTA-Peg-Cpa-c[DCys-Aph(Cbm)-DTrp-Lys-Thr-Cys]-2Nal-NH2 |
69 |
h |
2024-12-19 |
72614 |
DOTA-2.5D DOTA-胱氨酸结肽(knottins)2.5D和2.5F |
85 |
h |
2024-12-19 |
72615 |
二苯并环辛炔-四聚乙二醇-VAL-ALA-PAB,ADC定制 |
109 |
wyh |
2024-12-19 |
72616 |
Hz220(DOTA-Lys(IR dye 650)-PEa(4)-[D-Phe(6)DOTA偶联的GRPr拮抗剂 |
85 |
h |
2024-12-19 |
72617 |
Azido-PEG4-MMAE,抗体药物偶联物(ADCs) |
115 |
WYQ |
2024-12-19 |
72618 |
1626359-62-3,SPDB-DM4, ADC试剂 |
71 |
kx |
2024-12-19 |
72619 |
Acid-PEG4-Val-Cit-PAB-MMAE,包含PEG链和MMAE等部分 |
80 |
WYQ |
2024-12-19 |
72620 |
cas:159857-70-2,MC-Val-Cit-Doxorubicin,ADC定制 |
100 |
wyh |
2024-12-19 |
72621 |
DOTA-(D)Phe(1)-Tyr(3) |
76 |
h |
2024-12-19 |
72622 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
117 |
zyl |
2024-12-19 |
72623 |
FAM-amido hexamethylene carbamate-PAB-Cit-Val-Alkyne |
112 |
WYQ |
2024-12-19 |
72624 |
DOTA-l-Nal3-octreotide DOTA-l-nal3-奥曲肽 |
73 |
h |
2024-12-19 |
72625 |
CAS: 2762518-86-3 ,NHS ester-PEG4-Val-Cit-PAB-MMAE |
84 |
WYQ |
2024-12-19 |
72626 |
cas:2873452-49-2 ; MC-EVCit-PAB-MMAE,ADC定制 |
101 |
wyh |
2024-12-19 |
72627 |
CAS: 2762519-08-2 endo-BCN-PEG4-Val-Cit-PAB-MMAE,内末端二苯卡宾吡啶甲酸乙酯聚乙二醇4个单元赖氨酸缬氨酸丙氨酸天冬氨酸 |
127 |
WYQ |
2024-12-19 |
72628 |
cas:863971-24-8,Mc-MMAE ,马来酰亚胺基己酰-单甲基澳瑞他汀 E |
155 |
kx |
2024-12-19 |
72629 |
DOTA-(AEEA)2-BN DOTA-(AEEA)2-铃蟾肽 |
79 |
h |
2024-12-19 |
72630 |
cas:2259318-55-1 , DBCO-(PEG2-VC-PAB-MMAE)2,ADC定制 |
85 |
wyh |
2024-12-19 |